QEL-005

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameQEL-005
Drug Alias NameQEL-005QEL005
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, DiffuseScleroderma, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesQuell Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQuell Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, DiffuseScleroderma, Systemic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A